

IN THE COURT OF COMMON PLEAS  
PHILADELPHIA COUNTY, CIVIL TRIAL DIVISION

IN RE :  
: YAZ®, YASMIN®, OCELLA® : SEPTEMBER TERM, 2009  
LITIGATION : NO. 01307  
: :  
APPLICABLE TO ALL CASES :

**CASE MANAGEMENT ORDER NO. 4(h)**

**THIS MATTER**, having been opened to the Court by counsel for the Parties, and upon the Report and Recommended Decision of the Discovery Master;


**IT IS**, on this 5<sup>th</sup> day of May, 2011, hereby **ORDERED** as follows:

Case Management Order No. 4 (CMO/4) dated December 11, 2009, section

I(B)(2)(d) is hereby amended to append the following:

Notwithstanding the foregoing, (1) Defendants are prohibited from redacting business strategy, marketing, or sales information regarding Defendants' other Drospirenone ("DSRP")-containing medicines other than YAZ/Yasmin/Ocella, and Levonorgestral ("LNG")-containing combined oral contraceptives on documents heretofore produced; and (2) Defendants are required to un-redact any and all documents that have been redacted thus far on these grounds.

**SO ORDERED:**

  
\_\_\_\_\_  
THE HONORABLE SANDRA MAZER MOSS

In Re: Yaz/Yasmin/Ocella Litigation-ORDER



09090130700204

DOCKETED  
COMPLEX LIT CENTER

MAY 5 2011

J. STEWART